Clinical Trial Update: Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL [NA]

View source ↗

Summary

This clinical trial update describes a study of pomalidomide with rituximab and an anti-PD-1 antibody (PPR) for third- or later-line diffuse Large B-cell Lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Anti-PD-1 antibody
• Pomalidomide (Pomalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Diffuse Large B-cell Lymphoma (DLBCL) | NA | Status: RECRUITING